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Abstract
A “clickable” disaccharide was prepared by treating the aldehyde precursor with hydroxylamine,
followed by the catalytic hydrogenation and diazotransfer reaction. This disaccharide was
successfully applied to the elongation of the backbone construction of ultralow molecular weight
(ULMW) heparins using two bacterial glycosyl transferases, N-acetyl glucosaminyl transferase
from Escherichia coli K5 (KfiA) and heparosan synthase-2 (pmHS2) from Pasteurella multocida.
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1. Introduction
Heparan sulfate (HS) and heparin are linear, highly sulfated, anionic polysaccharides that
belong to the glycosaminoglycan (GAG) family.1 These GAGs are composed of a repeating
disaccharide motif of a glucuronic acid (GlcA) or an iduronic acid (IdoA) residue and a
glucosamine residue, including N-acetylglucosamine (GlcNAc), N-sulfoglucosamine
(GlcNS) or N-unsubstituted glucosamine (GlcNH2).2 HS is an abundant GAG on the surface
of mammalian cells and in the extracellular matrix. It plays regulatory roles in several
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pathophysiological processes, such as development, angiogenesis, blood coagulation, and
tumor metastasis.3,4,5
Preparation of pure GAG oligosaccharides is a major challenge for carbohydrate
chemists6,7,8 because traditional chemical synthesis of structurally defined GAGs relies on
the efficient introduction of protecting groups, epimerization of GlcA to IdoA,
stereoselective glycosylation, the efficient removal of protecting groups and sulfonation,
requiring a large number of synthetic steps to furnish the product.9,10,11 The biosynthesis of
GAGs in the Golgi of eukaryotic cells suggests a more efficient enzymatic route, which
includes the building of the polysaccharide backbone, as well as introducing sulfo groups
and IdoA residues.12,13 Employing a chemoenzymatic approach in our previous work, we
successfully synthesized the ULMW heparin heptasaccharides with 10 and 12 steps in 45%
and 37% overall yields based on the disaccharide acceptor degraded from heparosan (Figure
1), which showed very similar binding affinities and in vitro anti-Xa activities comparing
with the commercial drug Arixtra.14,15
The chemoenzymatic synthesis of structurally defined heparin oligosaccharide
glycoconjugates or immobilized heparin oligosaccharides might be accomplished through
the introduction of a reactive site into the heparin oligosaccharide. A heparin
oligosaccharide backbone can be elongated on a disaccharide acceptor to achieve this
goal.16 We report the synthesis of a disaccharide acceptor with an azido group as a reactive
site at the reducing end (Figure 1). This disaccharide acceptor can be applied to a “click”
reaction or released as a free amine group for diverse conjugation. This modified
disaccharide is quite suitable for use as an extendable acceptor for the backbone elongation
for the construction of ultralow molecular weight (ULMW) heparins.
2. Results and discussion
Heparosan (→4) GlcA (1→4) GlcNAc (1→)n17 has been prepared from the Escherichia
coli K5 strain18 and isolated at kilogram scale and was employed as starting material for our
disaccharide acceptor target (Scheme 1). Heparosan was dissolved in 2 M NaOH solution
under 60°C for 24 h to obtain the N-deacetylated heparosan polysaccharide according
previously described methods.19,20 The N-deacetylated heparosan polysaccharide was
deaminated with nitrous acid at low pH (~ 4.5), and neutralized with 2 M NaOH to furnish
disaccharide 4 (GlcA (1→4) anhydromannose (AnMan)).21,22 We found that the free
aldehyde group at the reducing end of disaccharide 4 was primarily obtained as the hydrate
form, hemiacetal 5. Hemiacetal 5 was identified by its 1H NMR and mass spectrum, which
showed the disappearance of the characteristic aldehyde peak, at ~9 ppm, and displayed the
hydrate form [M+H2O]−. The β-configuration of the glycosidic linkage was confirmed on
the basis of the 7.8 Hz J1,2 coupling constant, which indicates that the H-1II and H-2II atoms
are in a trans relationship to one another.23 Reductive amination of 5 was initially attempted
with sodium cyanoborohydride, however, low yields were achieved using both aliphatic and
aromatic amines. Treatment of 5 with hydroxylamine in aqueous sodium acetate solution
gave significantly improved yields (~90%), resulting in the formation of oxime 6 as a
mixture of the E and Z isomers.24 After the size exclusion chromatography, the 1H NMR
spectrum of oxime 6 showed doublets at 7.44 (J = 3.78 Hz) and 6.84 (J = 6.88 Hz)
corresponding to the presence of the CH=N group in an (E)-oxime to (Z)-oxime ratio of 7:2.
Reduction of oxime 6 was carried out smoothly employing hydrogen with Pd(OH)2/C
catalyst affording the corresponding amino derivative 7 in 91% yield. The structure of 7 was
confirmed by 1H and 2D NMR spectroscopy as it showed the disappearance of the CH=N
proton and the appearance of a multiplet at ~3.6 ppm, attributable to a newly formed CH2
group. Conversion of the amino group to an azido group was subsequently accomplished by
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treating 7 with sodium azide, Tf2O and catalytic CuSO4 in a combined CH2Cl2/MeOH/H2O
solution, furnishing compound 1 in 88% yield.25 The 13C NMR spectrum of compound 1
showed that C-1I shifted to 51.4 ppm, corresponding to a CH2 group after introducing an
azido group at the reducing end. Compound 1, an azido-functional acceptor, could be
employed to construct heparin oligosaccharide backbones. However, this disaccharide
acceptor always contained some impurities that were difficult to remove by the size
exclusion chromatography when performing large-scale reactions. Consequently, we
protected the carboxyl group with a methyl ester in 95% yield under acidic conditions and
the free hydroxyl groups as acetyl esters in quantitative yield to obtain compound 8, which
was easily purified on a silica column. Compound 8 was then quantitatively deprotected by
treating with 2M NaOH and desalted to obtain pure disaccharide acceptor 1 (Scheme 2).
Next, the heparin oligosaccharide backbone was prepared by enzymatic glycosylation of
disaccharide acceptor 1. Disaccharide 1 (GlcA-AnMan-N3) was incubated overnight with
UDP-GlcNTFA and KfiA at room temperature to furnish the trisaccharide product. Reverse-
phase ion-pairing HPLC (RPIP-HPLC) was employed to monitor the generation of uridine
diphosphate (UDP). Here, we employed an unnatural UDP-GlcNTFA donor, as it can be
readily converted to an N-sulfoglucosamine residue in a subsequent step.14 Afterwards, one
equivalent of UDP-GlcA was added into the above mixture and incubated for 4–5 h in the
presence of pmHS2, followed by addition of a second equivalent of UDP-GlcUA and
additional pmHS2 to ensure reaction completion. The resulting tetrasaccharide 9 was
recovered by size exclusion chromatography. The structures of the trisaccharide
intermediate and tetrasaccharide 9 were both confirmed by HR ESI-MS and NMR
spectroscopy.
3. Conclusions
We have developed a practical route including acidic depolymerization, oximation,
hydrogenation and diazotransfer reaction, towards the large scale preparation of the N3-
containing “clickable” acceptor, which was also successfully applied on the backbone
construction of ultralow molecular weight (ULMW) heparin oligosaccharide employing the




1H and 13C NMR spectra were recorded at 600 MHz for 1H NMR, 150 MHz for 13C NMR
or 800 MHz for 1H NMR, 200 MHz for 13C NMR with Topsin 2.1 software. Mass data were
acquired by high-resolution ESI-MS. Thin-layer chromatography (TLC) was carried out
using plates of silica gel 60 with fluorescent indicator and revealed with UV light (254 nm)
when possible and Von’s reagent or ninhydrin solution in ethanol. Flash chromatography
was performed using silica gel 230–400 mesh. Yields are given after purification, unless
otherwise noted. When reactions were performed under anhydrous conditions, the mixtures
were maintained under argon.
4.2. N-Deacetylation of Heparosan (3)
Heparosan 2 (3.3 g, 0.22 mmol) dissolved in 2 M NaOH (165 mL) was heated at 60 °C until
the solution is clear. After stirring for another 24 h under an argon atmosphere at 60 °C, the
solution was dialyzed with 1000 molecular weight cutoff (MWCO) dialysis membrane
against double-distilled water for 24 h. Then, the dialysate was lyophilized to give the N-
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deactylated heparosan (3) as yellow powder. Spectra were in agreement with reported
data.20
4.3. β-D-glucopyranosiduronate-(1→4)-2,5-Anhydro-D-mannose (4)
A 50 mL solution of 2:5 (1 M H2SO4: 5.5 M NaNO2) was added to dry N-deacetylated
heparosan 3 (2.0 g, 0.13 mmol), and vigorously stirred under ice bath for 30 min. After the
pH was adjusted to neutral with 30 mL of 3:5:5 (1 M Na2CO3: dd H2O: 1 M NaHCO3), the
solution was dialyzed using 1000 molecular weight cutoff (MWCO) dialysis membrane
against double-distilled water for 4 h and the dialysate was lyophilized to give the crude
product 4 as off-white powder (BuOH/HCOOH/H2O = 4:8:1, Rf = 0.44). 1H NMR (600
MHz, D2O): δ 4.95 (d, 1 H, J = 5.5 Hz, H-2I), 4.36 (d, 1 H, J = 7.8 Hz, H-1II), 4.23 (t, 1 H, J
= 5.0 Hz, H-3I), 3.99 (m, 1 H, H-5I), 3.97 (t, 1 H, J = 5.6 Hz, H-4I), 3.58-3.64 (m, 3 H,
H-5II, H-6bI, H-6aI), 3.36–3.40 (m, 2 H, H-3II), 3.20 (t, 1 H, J = 6.5 Hz, H-2II). Selected 13C
NMR (150 MHz, D2O): δ 102.0 (C-1II), 89.2 (C-2I), 85.7 (C-5I), 84.6 (C-4I), 82.0 (C-2I),
76.5 (C-3I), 75.1 (C-4II), 74.8 (C-5II), 72.8 (C-2II), 71.6 (C-3II); HRMS-FAB: [M−H]− m/z
calcd for C12H20O12: 355.0877; found: 355.0882.
4.3. β-D-glucopyranosiduronate-(1→4)-2,5-Anhydro-D-mannose oxime (6)
To a solution of 4 (450 mg, 1.33 mmol) in water hydroxylamine hydrochloride (0.11 g, 1.59
mmol) and sodium acetate (0.16 g, 1.91 mmol) were successively added. The solution was
stirred overnight at room temperature. The solvent was removed under reduced pressure and
the resulting syrup was purified by a Biogel P-2 column (1.5 × 200 cm) at a flow rate of 15
ml/h to give the crude product 6 (420 mg, 89.5%) as off-white powder (BuOH/HCOOH/
H2O = 4:8:1, Rf = 0.51). 1H NMR (600 MHz, D2O): δ 7.44 (d, 1 H, J = 3.78 Hz, CH=N(E)),
6.84 (d, 1H, J = 6.88 Hz, CH=N(Z)), 4.38 (d, 1 H, J = 7.8 Hz, H-1II), 4.28 (m, 1 H, H-3I),
4.05-4.04 (m, 2 H, H-4I, H-5I), 3.96 (m, 1 H, H-2I), 3.61–3.64 (m, 2 H, H-5II, H-6bI), 3.57
(m, 2 H, H-6aI)), 3.37 (m, 1 H, H-3II, H-4II), 3.20 (t, 1 H, J = 6.5 Hz, H-2II). Selected 13C
NMR (150 MHz, D2O): δ 102.0 (C-1II), 85.1 (C-5II), 82.1 (C-3I), 79.4 (C-4I), 77.8(C-2I),
75.1 (C-5I), 72.8 (C-2II), 71.6 (C-3II), 60.3 (C-6I); HRMS-FAB: [M−H]− m/z calcd for
C12H18NO11 352.0880; found, 352.0883.
4.4. β-D-glucopyranosiduronate-(1→4)-1-amino-2,5-anhydro-1-deoxy-D-mannitol (7)
Pd(OH)2-C 10% (0.19 g) was added to a solution of oxime 6 (240 mg, 0.68 mmol) in water
and several drops of acetic acid were subsequently added. The suspension was stirred under
H2 at atmospheric pressure and room temperature for 2 h. The solvent was removed under
reduced pressure and the resulting syrup was purified by a Biogel P-2 column (1.5 × 200
cm) at a flow rate of 15 ml/h to obtain compound 7 (210 mg, 0.62 mmol, 91%) as white
powder (BuOH/HCOOH/H2O = 4:8:1, Rf = 0.28). 1H NMR (600 MHz, D2O): δ 4.39 (d, 1
H, J = 7.6 Hz, H-1II), 4.04–4.08 (m, 2 H), 3.95 (s, 1 H), 3.91 (s, 1 H), 3.77–3.84 (m, 2 H),
3.70–3.75 (m, 1 H), 3.60–3.64 (m, 2 H), 3.55–3.59 (m, 1H), 3.41 (t, 1 H, J = 8.4 Hz), 3.36
(m, 1 H). Selected 13 C NMR (150 MHz, D2O): δ 103.1 (C-1II), 80.3, 76.6, 75.2 (C-5II),
72.8 (C-2II), 71.6 (C-3II), 71.0, 69.4, 68.8, 61.9, 61.1(C-6I); HRMS-FAB: [M−H]− m/z calcd
for C12H20NO10: 338.1087; found: 338.1088.
4.5. β-D-glucopyranosiduronate-(1→4)-2,5-anhydro-1-azido-1-deoxy-D-mannitol (1)
A solution of NaN3 (992 mg, 15.2 mmol) in 2.5 mL of H2O was cooled to ~0 °C in an ice
bath and subsequently added to 5 mL of CH2Cl2. A biphasic mixture generally formed that
was stirred vigorously and Tf2O (872 mg, 3.08 mmol) was slowly added drop-wise over a
period of 10 min. The reaction was then stirred under ice bath for 2 h, and the organic phase
was separated and aqueous phase was extracted with CH2Cl2 (2 × 2.5 mL). Then combined
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organic phase was extracted with saturated Na2CO3 solution and used without further
purification. The final concentration of TfN3 was 0.2 M in 10 mL solvent.
Substrate 7 (120 mg, 0.35 mmol) was dissolved in 5 mL of MeOH: H2O (1: 1). CuSO4 (2.8
mg, 0.018 mmol) and triethylamine (97 μL, 0.70 mmol, 2 equiv per amine substrate) were
added to the solution of substrate 7 with stirring. The mixture was cooled in an ice bath for
15 min, and 0.2 M CH2Cl2 solution of triflyl azide (2.1 mL, 1.2 equiv per amino group
based on the amount of triflic anhydride used in the preparation of TfN3) was added into the
above reaction solution dropwise. The reaction mixture was allowed to warm to room
temperature and a homogeneous solution was obtained after the addition. The reaction was
finished in 6 h as determined by monitoring triflyl azide by TLC (BuOH/HCOOH/H2O =
4:8:1, Rf = 0.56). The solvent was removed under reduced pressure and the resulting syrup
was purified by chromatography on a Biogel P-2 column (1.5 × 200 cm) eluted with water at
a flow rate of 15 ml/h. The fractions of the crude product 6 (412 mg, 88%) as off-white
powder were then collected and subjected to NMR and ESI-MS analysis. 1 H NMR (600
MHz, D2O): δ 4.38 (d, 1 H, J = 7.8 Hz, H-1II), 4.13 (t, 1 H, J = 5.7 Hz, H-3I), 3.99 (m, 2 H,
H-5I, H-4I), 3.91 (s, 1 H, H-2I), 3.64 (d, 1 H, J = 12.0 Hz, H-6bI), 3.63 (s, 1 H, H-5II), 3.59
(dd, 1 H, J = 4.7, 12.4 Hz, H-6aI), 3.52 (d, 1 H, J = 13.0 Hz, H-1bI), 3.40-3.35 (m, 3 H,
H-1aI, H-4II, H-3II), 3.22 (t, 1 H, J = 7.92 Hz, H-2II). 13C NMR (150 MHz, D2O): δ 175.6
(C-6II), 101.9 (C-1II), 85.4 (C-5I), 81.5 (C-4I), 80.9 (C-2I), 76.5 (C-3I), 75.3 (C-4II), 74.8
(C-5II), 72.8 (C-2II), 71.5 (C-3II), 60.9 (C-6I), 51.4 (C-1I); HRMS-FAB: [M−H]− m/z calcd
for C12H18N3O10, 364.0992; found: 364.1000.
4.6. Methyl 2,3,4-tri-O-acetyl-β-D-glucopyranosiduronate-(1→4)-3,6-di-O-acetyl-2,5-
anhydro-1-azido-1-deoxy-D-mannitol (8)
The crude compound 1 (45 mg, 0.12 mmol) was dissolved in 3 mL methanol, and 90 mg
Amberlite 120 (H+) resin was added into the solution. The mixture was vigorously stirred
for 12 h at room temperature. The resin was filtered to obtain the organic solvent, which was
concentrated under vacuum. The resulting residue was dissolved in 2 mL pyridine and 1 mL
Ac2O and was stirred for 12 h at room temperature. The organic solvent was concentrated
under reduced pressure, and the residue was purified by flash silica column chromatography
(EtOAc–Hexanes 1:2) giving compound 8 (67 mg, 95%) as syrupy. 1 H NMR (600 MHz,
CDCl3): δ 5.19 (t, 1 H, J = 9.5 Hz, H-4II), 5.16 (d, 1 H, J = 9.0 Hz, H-3II), 5.14 (t, 1 H, J =
3.5 Hz, H-3I), 4.95 (t, 1 H, J = 8.5 Hz, H-2II), 4.63 (d, 1 H, J = 7.5 Hz, H-1II), 4.14–4.16 (m,
1 H, H-4I), 4.13 (t, 1 H, J = 3.5 Hz, H-2I), 4.09–4.11 (m, 1 H, H-6bI), 4.03–4.09 (m, 2 H,
H-5I, H-6aI), 3.99 (d, 1 H, J = 9.5 Hz, H-5II), 3.68 (s, 3 H, OMe), 3.46 (dd, 1 H, J = 7.5, 13.0
Hz, H-1bI), 3.39 (dd, 1 H, J = 4.5, 13.0 Hz, H-1aI), 2.05 (s, 3 H, Ac), 2.01 (s, 3H, Ac), 1.99
(s, 3 H, Ac), 1.96 (s, 2 × 3 H, Ac). 13C NMR (150 MHz, CDCl3): δ 170.5 (C-6II), 166.9
(Ac), 100.6 (C-1II), 84.6 (C-5I), 82.8 (C-2I), 80.2 (C- 4I), 79.3 (C-3I), 72.6 (C-5II), 71.8
(C-4II), 70.8 (C-2II), 69.1 (C-3II), 63.0 (C-6I), 53.0 (OMe), 51.9 (C-1I); HRMS-FAB: [M
+H]+ m/z calcd for C23H32N3O15, 590.1833; found, 590.1840.
4.7. β-D-glucopyranosiduronate-(1→4)- α-D-2-trifluroacetamido-2-deoxy-glucopyranosyl-
(1→4)- β-D-glucopyranosiduronate-(1→4)-2,5-anhydro-1-azido-1-deoxy-D-mannitol (9)
To synthesize oligosaccharide backbone, disaccharide (GlcA-AnMan-N3, 1) (3.6 mg, 10
μmol) was incubated with UDP-GlcNTFA (8.5 mg, 12 μmol) and KfiA (0.1 mg) in 10 ml of
buffer containing 25 mM Tris-HCl (pH 7.2) and 10 mM MgCl2. The reaction was incubated
at room temperature overnight, and the reaction mixture was analyzed by a polyamine-based
HPLC column to ensure that 95% of UDP-GlcNTFA was converted to UDP. Then 10-μL of
reaction solution was passed through a 3000 MWCO spin-column and subjected to mass
spectral analysis. HRMS-FAB: [M−H]− m/z calcd for C20H28F3N4O15, 621.1503; found:
621.1509. Upon the complete consumption of UDP-GlcNTFA, pmHS2 (0.1 mg) and UDP-
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GlcA (7.5 mg, 12 μmol) were added into the reaction mixture for additional 4–5 h at room
temperature. Another portion of pmHS2 (0.1 mg) and UDP-GlcA (12 μmol) was added to
drive the transfer of GlcUA unit to completion. The product was purified using Biogel P-2
chromatography on a column (1.5 × 200 cm) that was equilibrated with 0.1 M ammonium
bicarbonate at a flow rate of 15 ml/h. The fraction containing the product was lyophilized to
give 9 (6.4 mg, 80%) and subjected to NMR and ESI-MS analysis. 1 H NMR (600 MHz,
D2O): δ 5.25–5.31 (m, 1 H), 4.38 (d, 1 H, J = 9.6 Hz), 4.35 (d, 1 H, J = 9.6 Hz), 4.29 (s, 1
H), 4.14 (t, 1 H, J = 5.4 Hz), 4.03 (t, 1 H, J = 5.4 Hz), 3.98 (dd, 1 H, J = 5.4, 10.2 Hz), 3.93–
3.95 (m, 1 H), 3.90 (dd, 1 H, J = 5.4, 10.2 Hz), 3.84–3.87 (m, 1 H), 3.69–3.75 (m, 2 H),
3.57–3.69 (m, 4 H), 3.52–3.56 (m, 1 H), 3.44–3.50 (m, 2 H), 3.34–3.39 (m, 3 H), 3.22 (t, 2
H, J = 8.2 Hz). HRMS-FAB: [M−H]− m/z calcd for C26H36F3N4O21, 797.1824; found:
797.1832.
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• A disaccharide was prepared by chemical treatment of heparosan
• An azido group was introduced into this heparosan disaccharide
• The azido heparosan disaccharide was used as a glycosylation acceptor
• A heparin tetrasaccharide was enzymatically synthesized
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Structures of targeted ULMW heparin oligosaccharides
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Synthesis of “clickable” disaccharide acceptor 1
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Chemoenzymatic synthesis of HS tetrasaccharide
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